Aripiprazole cardiosafety: Is it overestimated?

Aripiprazole is a third‐generation atypical (novel) antipsychotic, dihydroquinolinone, famously known as dopamine stabilizer, uniquely D2/D3 partial agonist, and 5HT1A agonist. It is a Food and Drug Administration‐approved drug for schizophrenia, bipolar mood disorder, augmentation in unipolar depression, irritability in autism, and Tourette syndrome in pediatric age group. It is lauded for being cardiometabolic‐friendly,[1] in stark contradistinction to most atypical antipsychotics currently on the market. Nelson and Leung[2] recently reported unusual QTc prolongation associated with aripiprazole use. Similarly, Hategan and Bourgeois[3] reported aripiprazole‐associated QTc prolongation in a geriatric patient. Lam,[4] too, noted QTc prolongation associated with aripiprazole. Suzuki et al.[5] reported a dose‐dependent of QTc interval at 30 mg of aripiprazole. Egger et al.[6] reported a case of dose‐dependent aripiprazole‐induced conduction disturbance. Torgovnick et al . [7] reported on aripiprazole‐induced orthostatic hypotension and supraventricular tachyarrhythmia. Shao et al.[8] reported a case of ventricular trigeminy induced by overdose aripiprazole.